Smith & Nephew has opened up to a possible break-up of the company amid activist pressure to consider a separation of its largest segment, its struggling orthopedics division, marking a shift in the company’s public position, reported The Times’ Alex Ralph. In a meeting with City analysts after Smith & Nephew’s full-year results last week, CFO John Rogers said the group remained committed to the turnaround of the largest of the group’s three units, but could consider options if its growth does not “sustainably improve” or does not result in a re-rating in the shares, The Times noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Smith & Nephew announces its efforts to develop technology in Spatial Surgery
- Smith & Nephew price target raised to 1,300 GBp from 1,250 GBp at Deutsche Bank
- Smith & Nephew Announces Share Capital Details
- Positive Outlook for Smith & Nephew: Buy Rating Driven by Strategic Initiatives and Market Growth Potential
- Smith & Nephew Snats (SNN) Announces Q2 Dividend: Read On for Important Dates
